New Report Available: Israel Pharmaceuticals & Healthcare Report Q2 2013
BMI View: The strength of Israel's R&D capabilities has been witnessed this quarter with an FDA approval of local company Brainway's Deep TMS (transcranial magnetic stimulation) medical device and positive Phase II clinical trial results for Neurim Pharmaceuticals' insomnia treatment. As leading Israeli generic drugmakers face increasing competition in light of global generic uptake, we expect to see a greater focus towards innovative medicines development and expansion of the country's biotechnology sector.
View full press release